SG Americas Securities LLC Purchases 15,777 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

SG Americas Securities LLC increased its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 61.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,270 shares of the company’s stock after buying an additional 15,777 shares during the quarter. SG Americas Securities LLC owned 0.05% of Tenaya Therapeutics worth $59,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. lifted its position in Tenaya Therapeutics by 204.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock worth $651,000 after buying an additional 226,466 shares during the last quarter. abrdn plc bought a new stake in Tenaya Therapeutics in the third quarter valued at approximately $1,063,000. State Street Corp lifted its position in Tenaya Therapeutics by 0.9% in the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after purchasing an additional 9,506 shares during the last quarter. Geode Capital Management LLC lifted its position in Tenaya Therapeutics by 5.4% in the third quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after purchasing an additional 66,968 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in Tenaya Therapeutics by 51.2% in the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after purchasing an additional 16,687 shares during the last quarter. Institutional investors own 90.54% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on TNYA shares. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Chardan Capital reissued a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group reissued a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Monday, February 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tenaya Therapeutics presently has an average rating of “Buy” and an average price target of $17.33.

Tenaya Therapeutics Stock Up 5.5 %

Shares of TNYA stock opened at $0.95 on Friday. The stock has a market cap of $75.03 million, a price-to-earnings ratio of -0.66 and a beta of 2.84. The business’s fifty day moving average is $1.58 and its 200 day moving average is $2.13. Tenaya Therapeutics, Inc. has a twelve month low of $0.86 and a twelve month high of $7.01.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.